author-photo

Li Li

Bristol-Myers Squibb

28

Papers

1389

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

A bridging immunogenicity assay for anti-cabiralizumab antibodies: overcoming the low assay cut point and drug tolerance challenges

2021 Bioanalysis
Show All
- Source
- Cite
- Save
Citations (0)
393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Rapid Development of a Bromochloropyridine Regioisomer Purity Method Enabled by Strategic LC Screening

2020 Journal of Pharmaceutical and Biomedical Analysis
Show All
- Source
- Cite
- Save
Citations (1)
CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

2018 Oncologist
Show All
- Source
- Cite
- Save
Citations (38)
Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups

2018 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (7)
Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

2018 Oral Oncology
Show All
- Source
- Cite
- Save
Citations (313)
1055PNivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)